Edwards Lifesciences

EW · NYSE

$88.29+$1.07 (+1.23%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $87.22

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Employees: 16,000
Headquarters: Irvine, California
Listed: Mar 27, 2000
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: edwards.com

Leadership

Edwards Lifesciences executives
Name	Title	Since	Age
Nicholas Valeriani	—	—	68
Bernard Zovighian	—	2016	57
Scott Ullem	—	—	58
Wayne Markowitz	—	—	53
Donald Bobo	—	—	63
Annette Bruls	—	—	54
Daveen Chopra	—	—	46
Daniel Lippis	—	—	49
Leslie Davis	—	—	66
David Feinberg	—	—	63
Kieran Gallahue	—	—	61
Leslie Heisz	—	—	64
Paul Laviolette	—	—	67
Steven Loranger	—	—	73
Ramona Sequeira	—	—	59

Revenue by product and region

Fiscal year ended Dec 31, 2019: $4.35B total revenue

By product

Transcatheter Aortic Valve Replacement$2.74B63.0%
Surgical Structural Heart$841.70M19.4%
Critical Care$740.20M17.0%
Transcatheter Mitral and Tricuspid Therapies$28.20M0.6%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Edwards Lifesciences suppliers and customers
Company	Relationship	Country	Correlation
Mentice AB (publ) MNTC.ST	Supplier	—	0.78
SurModics SRDX	Supplier and customer	—	0.60
CAE CAE.TO	Supplier and customer	—	0.59
Carmat ALCAR.PA	Customer	—	0.24
Benchmark Electronics BHE	Supplier	—	0.09
SEC Newgate S.p.A. SECN.L	Supplier	—	—
Carmat SA CKMTF	Customer	—	—
Medidata Solutions, Inc. MDSO	Supplier	—	—
Time, Inc. TIME	Supplier	—	—

Similar companies

Companies in the same industry as Edwards Lifesciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.